These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 6427266

  • 1. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
    Luder AS, Holland FJ, Costigan DC, Jenner MR, Wielgosz G, Fazekas AT.
    J Clin Endocrinol Metab; 1984 Jun; 58(6):966-72. PubMed ID: 6427266
    [Abstract] [Full Text] [Related]

  • 2. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, Francois R, Garandeau P, Lahlou N, Morel Y.
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [Abstract] [Full Text] [Related]

  • 3. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM, Harris DA, Egli CA, Conte FA, Kaplan SL, Rivier J, Vale W, Grumbach MM.
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [Abstract] [Full Text] [Related]

  • 4. [Subcutaneous and intranasal use of a LH-RH analog in the treatment of girls with central precocious puberty].
    Fideleff HL, Boquete HR, Azaretzky M, Damilano S, Cagide AL, Levalle O.
    Medicina (B Aires); 1989 Jul; 49(6):567-72. PubMed ID: 2518644
    [Abstract] [Full Text] [Related]

  • 5. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebaek NE.
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [Abstract] [Full Text] [Related]

  • 6. Effect of deslorelin dose in the treatment of central precocious puberty.
    Pescovitz OH, Barnes KM, Cutler GB.
    J Clin Endocrinol Metab; 1991 Jan; 72(1):60-4. PubMed ID: 1898743
    [Abstract] [Full Text] [Related]

  • 7. Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins.
    Rime JL, Zumsteg U, Blumberg A, Hadziselimovic F, Girard J, Zurbrügg RP.
    Eur J Pediatr; 1988 Apr; 147(3):263-9. PubMed ID: 3134243
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty.
    Holland FJ, Fishman L, Costigan DC, Luna L, Leeder S.
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1065-70. PubMed ID: 3093518
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up and final height in girls with central precocious puberty treated with luteinizing hormone-releasing hormone analogue nasal spray.
    Cacciari E, Cassio A, Balsamo A, Colli C, Cicognani A, Pirazzoli P, Tani G, Brondelli L, Mandini M, Bovicelli L.
    Arch Pediatr Adolesc Med; 1994 Nov; 148(11):1194-9. PubMed ID: 7921123
    [Abstract] [Full Text] [Related]

  • 10. Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome.
    Foster CM, Comite F, Pescovitz OH, Ross JL, Loriaux DL, Cutler GB.
    J Clin Endocrinol Metab; 1984 Oct; 59(4):801-5. PubMed ID: 6434582
    [Abstract] [Full Text] [Related]

  • 11. The treatment of central precocious puberty using an intranasal LHRH analogue (buserelin).
    Stanhope R, Adams J, Brook CG.
    Clin Endocrinol (Oxf); 1985 Jun; 22(6):795-806. PubMed ID: 3926352
    [Abstract] [Full Text] [Related]

  • 12. Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty.
    Comite F, Pescovitz OH, Rieth KG, Dwyer AJ, Hench K, McNemar A, Loriaux DL, Cutler GB.
    J Clin Endocrinol Metab; 1984 Nov; 59(5):888-92. PubMed ID: 6434587
    [Abstract] [Full Text] [Related]

  • 13. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report.
    Comite F, Cutler GB, Rivier J, Vale WW, Loriaux DL, Crowley WF.
    N Engl J Med; 1981 Dec 24; 305(26):1546-50. PubMed ID: 6458765
    [Abstract] [Full Text] [Related]

  • 14. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).
    Bourguignon JP, Van Vliet G, Vandeweghe M, Malvaux P, Vanderschueren-Lodeweyckx M, Craen M, Du Caju MV, Ernould C.
    Eur J Pediatr; 1987 Nov 24; 146(6):555-60. PubMed ID: 3123239
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation.
    Mansfield MJ, Beardsworth DE, Loughlin JS, Crawford JD, Bode HH, Rivier J, Vale W, Kushner DC, Crigler JF, Crowley WF.
    N Engl J Med; 1983 Nov 24; 309(21):1286-90. PubMed ID: 6415479
    [Abstract] [Full Text] [Related]

  • 16. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C, Craen M, Vanderschueren-Lodeweyckx M, Malvaux P, Fawe L, Bourguignon JP.
    Acta Paediatr; 1994 Jun 24; 83(6):627-33. PubMed ID: 7919761
    [Abstract] [Full Text] [Related]

  • 17. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB.
    J Clin Endocrinol Metab; 1999 Jan 24; 84(1):44-9. PubMed ID: 9920060
    [Abstract] [Full Text] [Related]

  • 18. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L, Pertzelan A, Weintrob N, Phillip M, Kauli R.
    J Clin Endocrinol Metab; 2001 Sep 24; 86(9):4127-32. PubMed ID: 11549638
    [Abstract] [Full Text] [Related]

  • 19. Treatment of central precocious puberty with an LHRH agonist (Buserelin): effect on growth and bone maturation after three years of treatment.
    Rappaport R, Fontoura M, Brauner R.
    Horm Res; 1987 Sep 24; 28(2-4):149-54. PubMed ID: 2969858
    [Abstract] [Full Text] [Related]

  • 20. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
    Marcondes JA, Abujamra AC, Minanni SL, Mendonca BB, Nery M, Lerario AC, Pereira MA, Abelin N, Wajchenberg BL.
    Horm Metab Res; 1993 Feb 24; 25(2):105-9. PubMed ID: 8458605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.